Delivery Order SPE2DB20D1109-SPE2DB25FP48N
- Not listed
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,844.37 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $37,112.83 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is being...
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $32,046.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 22, 2025, with completion targeted for July 23, 2025. This non-competitive, non-set-aside delivery order represents a child contract action under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The product will...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a $3,619.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 21, 2025, with completion scheduled for July 22, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award supports the company's role as a prime pharmaceutical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $6,223.32 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) effective July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP48NDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,071.19 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed price, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor agreement running through December 2026 that supplies medications and medical supplies globally to military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This specific delivery order for RINVOQ, a rheumatoid arthritis treatment, exemplifies the company's role in supplying essential medications to support military medical readiness and veteran healthcare needs through the DLA's established pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 7/29/25 |